Professional profile: Stephen T. Sonis, D.M.D.,
Post# of 72440
Posted On: 03/17/2016 11:19:29 PM
Professional profile:
Stephen T. Sonis, D.M.D., D.M.Sc.
Founder, Partner, Chief Scientific Officer
Dr. Sonis is a world-renowned expert in epithelial injury associated with cancer therapy. His development of predictive animal models has enabled the investigation of the biological basis of mucositis and has assisted in the development of potential therapies. The results of his studies on the molecular and cellular pathogenesis of mucositis have established the basis of the mechanistic paradigm for mucosal injury. Dr. Sonis' interest in the genomic basis for toxicity risk and its pathology has led to innovative genomics-based analytical approaches to clinically actionable outcomes to personalize disease therapy. Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He is the author of over 200 original publications, reviews and chapters, 9 books, and 5 patents. Dr. Sonis has obtained degrees from Tufts University and Harvard University and completed his post-doctoral education (tumor immunology) at Oxford University. He holds appointments at the Harvard School of Dental Medicine (Clinical Professor of Oral Medicine, Department of Oral Medicine, Infection and Immunity), the Dana-Farber Cancer Institute and Brigham and Women's Hospital where he is Division Chief and Senior Surgeon.
http://www.biomodels.com/about/professional-profiles/
Stephen T. Sonis, D.M.D., D.M.Sc.
Founder, Partner, Chief Scientific Officer
Dr. Sonis is a world-renowned expert in epithelial injury associated with cancer therapy. His development of predictive animal models has enabled the investigation of the biological basis of mucositis and has assisted in the development of potential therapies. The results of his studies on the molecular and cellular pathogenesis of mucositis have established the basis of the mechanistic paradigm for mucosal injury. Dr. Sonis' interest in the genomic basis for toxicity risk and its pathology has led to innovative genomics-based analytical approaches to clinically actionable outcomes to personalize disease therapy. Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He is the author of over 200 original publications, reviews and chapters, 9 books, and 5 patents. Dr. Sonis has obtained degrees from Tufts University and Harvard University and completed his post-doctoral education (tumor immunology) at Oxford University. He holds appointments at the Harvard School of Dental Medicine (Clinical Professor of Oral Medicine, Department of Oral Medicine, Infection and Immunity), the Dana-Farber Cancer Institute and Brigham and Women's Hospital where he is Division Chief and Senior Surgeon.
http://www.biomodels.com/about/professional-profiles/
(0)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Scroll down for more posts ▼